Next Article in Journal
Virus-Like Particle Facilitated Deposition of Hydroxyapatite Bone Mineral on Nanocellulose after Exposure to Phosphate and Calcium Precursors
Next Article in Special Issue
Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy
Previous Article in Journal
Leishmania infantum β-Tubulin Identified by Reverse Engineering Technology through Phage Display Applied as Theranostic Marker for Human Visceral Leishmaniasis
Previous Article in Special Issue
Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diagnosis

A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges

Henry Jackson Foundation for the Advancement of Military Medicine (HJF), Bethesda, MD 20817, USA
Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center, Bethesda, MD 20814, USA
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(8), 1813;
Received: 27 March 2019 / Revised: 8 April 2019 / Accepted: 9 April 2019 / Published: 12 April 2019
Prostate cancer is the most prevalent non-skin cancer in men and is the leading cause of cancer-related death. Early detection of prostate cancer is largely determined by a widely used prostate specific antigen (PSA) blood test and biopsy is performed for definitive diagnosis. Prostate cancer is asymptomatic in the early stage of the disease, comprises of diverse clinico-pathologic and progression features, and is characterized by a large subset of the indolent cancer type. Therefore, it is critical to develop an individualized approach for early detection, disease stratification (indolent vs. aggressive), and prediction of treatment response for prostate cancer. There has been remarkable progress in prostate cancer biomarker discovery, largely through advancements in genomic technologies. A rich array of prostate cancer diagnostic and prognostic tests has emerged for serum (4K, phi), urine (Progensa, T2-ERG, ExoDx, SelectMDx), and tumor tissue (ConfirmMDx, Prolaris, Oncoytype DX, Decipher). The development of these assays has created new opportunities for improving prostate cancer diagnosis, prognosis, and treatment decisions. While opening exciting opportunities, these developments also pose unique challenges in terms of selecting and incorporating these assays into the continuum of prostate cancer patient care. View Full-Text
Keywords: prostate cancer; molecular biomarkers; diagnosis; prognosis prostate cancer; molecular biomarkers; diagnosis; prognosis
Show Figures

Figure 1

MDPI and ACS Style

Kohaar, I.; Petrovics, G.; Srivastava, S. A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges. Int. J. Mol. Sci. 2019, 20, 1813.

AMA Style

Kohaar I, Petrovics G, Srivastava S. A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges. International Journal of Molecular Sciences. 2019; 20(8):1813.

Chicago/Turabian Style

Kohaar, Indu, Gyorgy Petrovics, and Shiv Srivastava. 2019. "A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges" International Journal of Molecular Sciences 20, no. 8: 1813.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop